Taletrectinib adipate is under clinical development by Nuvation Bio and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Taletrectinib adipate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Taletrectinib adipate overview
Taletrectinib (DS-6051b/AB-106) is under development for the treatment of relapsed or refractory solid tumors including k-RAS wild-type colorectal cancer, neuroendocrine tumors, non-small-cell lung carcinoma (NSCLC), primary CNS tumors, brain metastases, metastatic breast cancer and pulmonary large-cell neuroendocrine carcinoma (LCNEC). It is administered orally as a capsule. The drug candidate targets tyrosine kinases ROS1 and NTRKs type 1, 2, 3.
Nuvation Bio overview
Nuvation Bio is a biotechnology company developing proprietary therapies focused on oncology. The companies proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company is headquartered in New York City, New York, the US.
For a complete picture of Taletrectinib adipate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
